Startups
OpGen is uniquely positioned to address the rising antibiotic resistance crisis and is harnessing the power of informatics and genomic analysis to provide complete solutions to protect patients in hospitals and healthcare networks.
Using our large and ever-growing Acuitas Lighthouse® Knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases.
Today, through our CLIA-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. Our FDA-cleared, IVD products rapidly identify pathogens in positive blood cultures.
Using our large and ever-growing Acuitas Lighthouse® Knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases.
Today, through our CLIA-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. Our FDA-cleared, IVD products rapidly identify pathogens in positive blood cultures.
Overview
Location
Austria, Vienna
Employees
51-200
Total raised
$17M
Founded date
2017
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 27
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 4, 2023 | OpGen Announces Closing of $3.5 Million Public Offering | |
| May 1, 2023 | OpGen Announces Pricing of $3.5 Million Public Offering | |
| Jan 11, 2023 | OpGen Announces Closing of $7.5 Million Public Offering | /EIN News/ -- ROCKVILLE, Md., Jan. 11, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious di... |
| Jan 11, 2023 | OpGen Announces Closing of $7.5 Million Public Offering | |
| Jan 7, 2023 | OpGen Announces Pricing of $7.5 Million Public Offering | /EIN News/ -- ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious di... |
| Jan 6, 2023 | OpGen Announces Pricing of $7.5 Million Public Offering | |
| Oct 18, 2021 | OpGen Announces Closing of $15 Million Registered Direct Offering | ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today a... |
| Oct 18, 2021 | OpGen : Announces Closing of $15 Million Registered Direct Offering | ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today a... |
| Oct 15, 2021 | OpGen : Announces $15 Million Registered Direct Offering - Form 8-K | OpGen Announces $15 Million Registered Direct Offering ROCKVILLE, Md., Oct. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, "OpGen" or the "Company"), a precision medicine company harnessing the power of molecula... |
Show more
Reviews 0
FAQ about Ares Genetics
When was Ares Genetics founded?
Ares Genetics was founded in 2017.
How much funding has Ares Genetics raised?
Ares Genetics has raised $17M in total across 1 funding round.
What has the press written about Ares Genetics?
Parsers VC has collected 27 articles mentioning Ares Genetics, among them “OpGen Announces Closing of $3.5 Million Public Offering” (May 4, 2023) and “OpGen Announces Pricing of $3.5 Million Public Offering” (May 1, 2023).
Is Ares Genetics still active?
Yes, Ares Genetics is active; its latest activity on Parsers VC dates from Jan 11, 2023.